Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis.
Hepatic aldose reductase (AR) expression is known to be induced in liver diseases, including hepatitis and hepatocellular carcinoma. However, the role of AR in the development of these diseases remains unclear. We performed this current study to determine whether and how AR might be involved in the development of diet-induced nonalcoholic steatohepatitis. Our results showed that the level of AR protein expression was significantly higher in db/db mice fed the methionine-choline-deficient (MCD) diet than in mice fed the control diet. In parallel with the elevation in AR, steatohepatitis was observed in MCD diet-fed mice, and this diet-induced steatohepatitis was significantly attenuated by lentiviral-mediated knock-down of the AR gene. This suppressive effect of AR knock-down was associated with repressed levels of serum alanine aminotransferase and hepatic lipoperoxides, reduced mRNA and protein expression of hepatic cytochrome P450 2E1 (CYP2E1), and decreased mRNA expression of pro-inflammatory tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). Moreover, AR-induced elevations on the level of CYP2E1 expression, reactive oxygen species, mRNA expression of TNF-α and IL-6 were confirmed in AML12 hepatocytes. Further, lentiviral-mediated knock-down of AR ameliorated MCD diet-induced collagen deposition in the livers of db/db mice. With the improvement in liver fibrosis, the mRNA levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and matrix metalloproteinase-2 (MMP-2), two genes involved in hepatic fibrogenesis, were found to be significantly suppressed, while TIMP-2 and MMP-13 were unaffected. Together these data indicate that inhibition of AR alleviates the MCD diet-induced liver inflammation and fibrosis in db/db mice, probably through dampening CYP2E1 mediated-oxidative stress and ameliorating the expression of pro-inflammatory cytokines.
School of Life Sciences, Longyan University, Longyan, China ; Fujian Key Laboratory of Preventive Veterinary Medicine and Biotechnology (Longyan University), Longyan, China.
Longxin
L
Qiu
Jianhui
J
Lin
Miao
M
Ying
Weiqiang
W
Chen
Jinmei
J
Yang
Tiantian
T
Deng
Jinfeng
J
Chen
Duanyu
D
Shi
James Y
JY
Yang
D000449:Aldehyde Reductase / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D015153:Blotting, Western; D002794:Choline; D004032:Diet / Q000009:adverse effects*; D005234:Fatty Liver / Q000201:enzymology* / Q000209:etiology / Q000235:genetics; D005260:Female; D015850:Interleukin-6 / Q000235:genetics; D053509:Matrix Metalloproteinase 13 / Q000235:genetics; D020778:Matrix Metalloproteinase 2 / Q000235:genetics; D008715:Methionine / Q000172:deficiency; D051379:Mice; D065626:Non-alcoholic Fatty Liver Disease; D017382:Reactive Oxygen Species / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000235:genetics; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
D015850:Interleukin-6; D017382:Reactive Oxygen Species; D019715:Tissue Inhibitor of Metalloproteinase-1; D014409:Tumor Necrosis Factor-alpha; D008715:Methionine; D000449:Aldehyde Reductase; D053509:Matrix Metalloproteinase 13; D020778:Matrix Metalloproteinase 2; D002794:Choline